<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02826291</url>
  </required_header>
  <id_info>
    <org_study_id>OSNA-EC-01</org_study_id>
    <nct_id>NCT02826291</nct_id>
  </id_info>
  <brief_title>SLNM in Endometrial Cancer Combined With OSNA</brief_title>
  <acronym>SLNM/OSNA</acronym>
  <official_title>Sentinel Lymph Node Mapping in Endometrial Cancer Patients Combined With One-step Nucleic Acid Amplification (OSNA)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Charles University, Czech Republic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University Hospital Pilsen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Charles University, Czech Republic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to compare one-step nucleic acid amplification method (OSNA) with
      histological ultrastaging examination in the sentinel lymph node assessment in patients with
      endometrial cancer.

      The molecular biologic method OSNA is a modern way of metastatic spread detection in
      lymphatic nodes using quantitative reverse transcription polymerase chain reaction.
      Cytokeratin 19 (CK 19) was selected based on previous studies as the optimal mRNA marker
      (detected by OSNA).

      The intraoperative identification and rapid assessment of sentinel lymph nodes by OSNA could
      help to improve the standards of care in endometrial cancer patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Method:

      After the sentinel lymph node detection (ICG, 99m Tc or Bleu Patente) and sentinel node/nodes
      removal is performed, the node/nodes is/are cut in 2-mm slices parallel to short axis of the
      node. The odd-numbered blocks will be examined by the OSNA method and the even-numbered
      blocks will be examined by conventional histopathological methods including
      immunohistochemistry.

      Statistical analysis to identify differences will be performed subsequently.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2016</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>number of CK 19 copies detected by OSNA</measure>
    <time_frame>14 days</time_frame>
    <description>Number of CK 19 copies will be assessed: 250-5000 micrometastasis, more than 5000 copies macrometastasis. This result will be compared to histological ultrastaging examination.</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">31</enrollment>
  <condition>Endometrial Cancer</condition>
  <arm_group>
    <arm_group_label>RD-100i, OSNA</arm_group_label>
    <description>SLNM and OSNA assessment of sentinel lymph nodes compared to ultrastaging</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>RD-100i, OSNA</intervention_name>
    <description>quantitative reverse transcription polymerase chain reaction (qRT-PCR) cytokeratin-19 detection in specimen (sentinel lymph node)</description>
    <arm_group_label>RD-100i, OSNA</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Samples of the tissue homogenate will be retained and may be used for further testing.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients older than 18 years diagnosed with endometrial cancer.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Endometrial cancer

          -  Signed informed consent

        Exclusion Criteria:

          -  Inclusion criteria not met

          -  Pregnant patients

          -  Patients participating in other clinical studies

          -  Patients who have been judged to be an inappropriate candidate by any medical care
             provider
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ondřej Topolčan, Prof. MUDr.</last_name>
    <role>Study Chair</role>
    <affiliation>Department of Nuclear Medicine, Medical School and Teaching Hospital in Pilsen, Charles University in Prague, Prague, Czech Republic</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Zdeněk Novotný, Doc.MUDr.</last_name>
    <role>Study Chair</role>
    <affiliation>Department of Obstetrics and Gynaecology, University Hospital in Pilsen, Charles University in Prague, Czech Republic</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jan Kosťun, MUDr.</last_name>
    <phone>00420-776698419</phone>
    <email>jan.kostun@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jiří Presl, MUDr., Ph.D.</last_name>
    <phone>00420-736679845</phone>
    <email>jiri.presl77@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Faculty Hospital in Pilsen</name>
      <address>
        <city>Pilsen</city>
        <zip>30460</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jan Kosťun, MUDr.</last_name>
      <phone>00420-776698419</phone>
      <email>jan.kostun@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Jiří Presl, MUDr., Ph.D.</last_name>
      <phone>00420-736679845</phone>
      <email>jiri.presl77@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Jan Kosťun, MUDr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Czech Republic</country>
  </location_countries>
  <reference>
    <citation>Nagai T, Niikura H, Okamoto S, Nakabayashi K, Matoda M, Utsunomiya H, Nagase S, Watanabe M, Takeshima N, Yaegashi N. A new diagnostic method for rapid detection of lymph node metastases using a one-step nucleic acid amplification (OSNA) assay in endometrial cancer. Ann Surg Oncol. 2015 Mar;22(3):980-6. doi: 10.1245/s10434-014-4038-2. Epub 2014 Sep 5.</citation>
    <PMID>25190122</PMID>
  </reference>
  <reference>
    <citation>Yamamoto H, Sekimoto M, Oya M, Yamamoto N, Konishi F, Sasaki J, Yamada S, Taniyama K, Tominaga H, Tsujimoto M, Akamatsu H, Yanagisawa A, Sakakura C, Kato Y, Matsuura N. OSNA-based novel molecular testing for lymph node metastases in colorectal cancer patients: results from a multicenter clinical performance study in Japan. Ann Surg Oncol. 2011 Jul;18(7):1891-8. doi: 10.1245/s10434-010-1539-5. Epub 2011 Feb 3.</citation>
    <PMID>21290195</PMID>
  </reference>
  <reference>
    <citation>Okamoto S, Niikura H, Nakabayashi K, Hiyama K, Matoda M, Takeshima N, Watanabe M, Nagase S, Otsuki T, Yaegashi N. Detection of sentinel lymph node metastases in cervical cancer: assessment of KRT19 mRNA in the one-step nucleic acid amplification (OSNA) method. Gynecol Oncol. 2013 Sep;130(3):530-6. doi: 10.1016/j.ygyno.2013.06.027. Epub 2013 Jun 28. Erratum in: Gynecol Oncol. 2013 Dec;131(3):791.</citation>
    <PMID>23811115</PMID>
  </reference>
  <reference>
    <citation>Buglioni S, Di Filippo F, Terrenato I, Casini B, Gallo E, Marandino F, Maini CL, Pasqualoni R, Botti C, Di Filippo S, Pescarmona E, Mottolese M. Quantitative molecular analysis of sentinel lymph node may be predictive of axillary node status in breast cancer classified by molecular subtypes. PLoS One. 2013;8(3):e58823. doi: 10.1371/journal.pone.0058823. Epub 2013 Mar 22.</citation>
    <PMID>23533593</PMID>
  </reference>
  <reference>
    <citation>Mariani A, Webb MJ, Keeney GL, Podratz KC. Routes of lymphatic spread: a study of 112 consecutive patients with endometrial cancer. Gynecol Oncol. 2001 Apr;81(1):100-4.</citation>
    <PMID>11277658</PMID>
  </reference>
  <reference>
    <citation>Colombo N, Creutzberg C, Amant F, Bosse T, González-Martín A, Ledermann J, Marth C, Nout R, Querleu D, Mirza MR, Sessa C; ESMO-ESGO-ESTRO Endometrial Consensus Conference Working Group. ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: Diagnosis, Treatment and Follow-up. Int J Gynecol Cancer. 2016 Jan;26(1):2-30. doi: 10.1097/IGC.0000000000000609.</citation>
    <PMID>26645990</PMID>
  </reference>
  <reference>
    <citation>Kim CH, Soslow RA, Park KJ, Barber EL, Khoury-Collado F, Barlin JN, Sonoda Y, Hensley ML, Barakat RR, Abu-Rustum NR. Pathologic ultrastaging improves micrometastasis detection in sentinel lymph nodes during endometrial cancer staging. Int J Gynecol Cancer. 2013 Jun;23(5):964-70. doi: 10.1097/IGC.0b013e3182954da8.</citation>
    <PMID>23694985</PMID>
  </reference>
  <reference>
    <citation>Leitao MM Jr, Khoury-Collado F, Gardner G, Sonoda Y, Brown CL, Alektiar KM, Hensley ML, Soslow RA, Barakat RR, Abu-Rustum NR. Impact of incorporating an algorithm that utilizes sentinel lymph node mapping during minimally invasive procedures on the detection of stage IIIC endometrial cancer. Gynecol Oncol. 2013 Apr;129(1):38-41. doi: 10.1016/j.ygyno.2013.01.002. Epub 2013 Jan 12.</citation>
    <PMID>23321065</PMID>
  </reference>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 5, 2016</study_first_submitted>
  <study_first_submitted_qc>July 6, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 7, 2016</study_first_posted>
  <last_update_submitted>January 30, 2017</last_update_submitted>
  <last_update_submitted_qc>January 30, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 1, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Charles University, Czech Republic</investigator_affiliation>
    <investigator_full_name>Jan Kosťun</investigator_full_name>
    <investigator_title>MUDr.</investigator_title>
  </responsible_party>
  <keyword>OSNA</keyword>
  <keyword>sentinel</keyword>
  <keyword>lymph</keyword>
  <keyword>node</keyword>
  <keyword>endometrial</keyword>
  <keyword>cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Endometrial Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

